Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomized, phase 3 trial
The Lancet Nov 28, 2019
Heijerman HGM, McKone EF, Downey DG, et al. - In this phase 3, multicentre, randomized, double-blind, active-controlled trial of elexacaftor in combination with tezacaftor plus ivacaftor conducted at 44 sites in four countries of 113 individuals with cystic fibrosis homozygous for the F508del mutation, aged 12 years or older with stable disease, and with a percentage prognosticated forced expiratory volume in 1 of 40–90%, inclusive, experts ascertained the efficiency and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in individuals with cystic fibrosis homozygous for the F508del mutation. In comparison with tezacaftor plus ivacaftor alone, in the lives of persons with cystic fibrosis who are homozygous for the F508del mutation, a clinically strong advantage and a favorable safety profile by elexacaftor plus tezacaftor plus ivacaftor along with the potential to result in transformative developments was given.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins